Acadia Pharmaceuticals | ACAD - Current Assets

Stock Price
23.99
Daily Change
-0.34 -1.40%
Monthly
-10.35%
Yearly
20.25%
Q1 Forecast
23.25

Acadia Pharmaceuticals reported $1.08B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
ALKERMES USD 1.74B 106.38M Sep/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cara Therapeutics USD 43.13M 4.18M Jun/2025
Corcept Therapeutics USD 541.13M 98.02M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Eisai JPY 840.88B 50.18B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Prothena USD 339.97M 45.51M Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025